Navigation Links
Shire Proposes to Expand Specialist Gastrointestinal Portfolio
Date:8/3/2010

    DUBLIN, August 3, 2010 /PRNewswire-FirstCall/ --

    - Proposed recommended cash acquisition of specialty gastrointestinal
      (GI) company Movetis NV for a fully diluted equity purchase price of
      EUR428 million in cash. As at March 31, 2010, their last reporting
      date, Movetis held EUR100 million in cash; based on this the
      enterprise value of Movetis (less cash) would be EUR328 million
    - Strong strategic fit with Shire's growing core GI business; RESOLOR(R)
      brings an additional approved GI medicine with strong patent
      protection addressing a symptomatic unmet need
    - The acquisition of Movetis is value and growth enhancing, will be
      earnings accretive after 2012, and adds immediate revenues from the
      recently launched RESOLOR to Shire's GI portfolio
    - Proposed acquisition of Movetis brings to Shire world-class research
      and development talent and a promising GI pipeline, offering additional
      opportunities that include two projects in early clinical development
      and several pre-clinical leads as well as the rights to a large library
      of qualified lead compounds with potential for development in different
      GI indications
    - Broadens Shire's international specialty product portfolio and further
      expands its ex-US business
    - Movetis has rights to RESOLOR in the 27 countries of the European
      Union, plus Iceland, Lichtenstein, Norway and Switzerland. RESOLOR is
      approved in 30 of these countries and is already launched in Germany
      and the UK. Shire anticipates further launches in other European
      countries in the next 12 months. Movetis is entitled to receive
      royalties on sales of RESOLOR outside of Europe from Johnson & Johnson
    - RESOLOR is a new chemical entity with composition of matter patent
      protection extending through 2020 and Shire estimates potential annual
      pea
'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
2. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
3. Shire plc Appoints Two New Board Directors
4. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
5. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
6. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
7. Shires Replenished Portfolio Drives Excellent Quarterly Performance
8. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
9. Shire Supports Rare Disease Day 2010
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... The latest addition to ... which prints and verifies labels automatically. Companies in the pharmaceutical and healthcare industry can ... up to 500 per minute. The Label Serialization Station can be fully integrated into ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... 18 months ago. Conventional treatment and therapy were not working so Zach decided ... 2015. Dr. McKenna treated Zack with precisely guided injections of bone marrow aspirate ...
(Date:9/3/2015)... , Sept. 3, 2015  Guardant Health®, ... five abstracts highlighting the performance and clinical utility ... accepted for oral and poster presentations at the ... 16th World Conference on Lung Cancer. These abstracts ... University of California, Davis; the University of Chicago; ...
(Date:9/3/2015)... AUSTIN, Texas , Sept. 3, 2015  Vermillion, ... focused on gynecologic disease, today announced that Herbert ... owned subsidiary, ASPiRA LABS, is the recipient of the ... Oncology and Biomarkers (ISOBM) for outstanding contributions to the ... receive the award on October 5 th in ...
Breaking Biology Technology:Print and Verify Labels On The Production Line With New Label Serialization Stations 2Print and Verify Labels On The Production Line With New Label Serialization Stations 3UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 2UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 4Vermillion Announces Dr. Herbert Fritsche as Recipient of the 2015 Abbott Award from the International Society of Oncology and Biomarkers 2
... YORK, Feb. 17 The following is from Betsy ... "Ruin Your Health With the Obama Stimulus Plan."I am ... a correction. Mr. Olbermann charges that I, Betsy McCaughey, ... industry, the biotech industry, the Hudson Institute, or Cantel ...
... Mass., Feb. 17 Idenix Pharmaceuticals, Inc. (Nasdaq: ... development of drugs for the treatment of human viral and ... fourth quarter and year ended December 31, 2008. At December ... $46.1 million. Business Highlights , , ...
... ... DE (Vocus) February 17, 2009 -- DuPont today announced that ... are in compliance with the Excellence Through StewardshipSM (ETS) ... confirms that the company uses the tools of biotechnology ethically and ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 7DuPont Biotech Stewardship Program Gains External Certification 2DuPont Biotech Stewardship Program Gains External Certification 3
(Date:9/2/2015)... , Sept. 2, 2015 About hand geometry ... enterprises, banks, government organizations, telecommunication and hospitals as well ... identity badges, and numeric keypads are used to prevent ... of palm and fingers of an individual, width of ... scanners with infrared light and reflectors can be used ...
(Date:9/2/2015)... Sept. 2, 2015 Security of data ... enterprises, banks, government organizations, telecommunications, hospitals, as well ... were previously being used to prevent unauthorised access. ... authentication, wherein individuals could gain access to secure ... such as hardware devices and numeric codes. However, ...
(Date:9/2/2015)... 2015 Biometric technology ... a system which uses identical human characteristic such ... DNA and finger print. Increasing number of terror ... system which provides high level of security. Traditional ... tokens are vulnerable to attacks. Furthermore, Biometric technology ...
Breaking Biology News(10 mins):Global Hand Geometry Biometrics Market 2015-2019 2Global Hand Geometry Biometrics Market 2015-2019 3Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4
... In unprecedented new research, scientists at Rice University ... time to both predict theoretically and verify experimentally ... , The interdisciplinary research appears this week in ... National Academy of Sciences. , "Researchers have successfully ...
... computerized system to easilymonitor the levels of glucose in ... published today in the open access journal BMC MedicalInformatics ... assists in the monitoring of glucose levels incritically ill ... than the paper-based method currently used in manyintensive care ...
... protein called vasostatin may prove a promising new way of ... Gut. , Pancreatic cancer is the fifth leading cause of ... to treat. Only 3% of affected patients are still alive ... static for the past three decades. , Currently, the only ...
Cached Biology News:Free-energy theory borne out in large-scale protein folding 2Free-energy theory borne out in large-scale protein folding 3Jefferson researchers find nanoparticle shows promise in reducing radiation side effects 2
Provides continuous mixing action. For use with tubes, vials, and other containers...
... and Gel Band Purification Kit, 100. For the ... DNA fragments (0.1-10 kb) from solution and from ... fragments from solution in as little as 5 ... 15 min.Prepacked glass fiber matrix columns provide consistent ...
Bethyl Laboratories Epitope Retrieval Buffer-Reduced pH will unmask antigenic sites from formaldehyde fixation and allow for subsequent immunostaining. Shelf-Life: 1 year from date of receipt...
Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures. Shelf-Life: 1 year from date of receipt...
Biology Products: